Tarsus has commenced its Phase 2 Calliope trial by dosing the first participant with TP-05, a novel oral prophylactic intended to kill Lyme-infected ticks before disease transmission. This randomized, double-blind, placebo-controlled study will enroll approximately 700 healthy adults at risk for Lyme disease to assess safety, tolerability and pharmacokinetics. In the preceding Phase 2a Carpo trial, a single dose of TP-05 achieved over 90% tick mortality within 24 hours of attachment compared to 5% with placebo (p<0.001), demonstrating durable efficacy at both Day 1 and Day 30 alongside a favorable tolerability profile. Tarsus plans to complete enrollment during the 2026 tick season and expects topline results in the first half of 2027. These data will inform potential advancement toward regulatory discussions for what could become the first FDA-approved pharmacological prophylactic option for Lyme disease prevention.